On July 14, 2026, underwriters fully exercised their option to purchase an additional 1,500,000 Class A ordinary shares in the previously announced public offering. This exercise generated $30.0 million in additional gross proceeds for the company. MoonLake Immunotherapeutics is a biotechnology company focused on developing immunotherapies.
